While the Human Genome Project was declared complete 20 years ago, the mapping of the human genome was not truly complete. As the author of today’s article explains, “About 8% of our genetic instructions remained untouched even after the sequencing project officially ended.” But thanks in large part to new sequencing technology from the biotech he proceeds to highlight, those missing parts of the genetic map may now have been filled in – and the possibilities this opens up could generate huge gains for the company’s shareholders going forward. For more, CLICK HERE.
Filling In The Missing Parts Of The Genetic Map Could Translate Into Huge Gains For This Biotech
- by RobH
Tags:Biotech InvestingBiotech SectorGenetic MapHuman Genome ProjectInvestingInvestmentShareholdersStock Marketstocks